About 3 quarters of cash left based on last quarter costs. More if current options in the money are converted.
All con notes used have been paid off. I believe they can still call on remaining con notes for extra funding in future but all debt is paid for now and they are cashed up.
While revenue is increasing and the costs for FDA approval are behind us, they are planning on spending money on expanding the FebriDx product market reach as outlined in their CR intentions.
I don't see a cap raise any time soon, but if a big contract or distribution partner comes up there may be one based on new investors and accelerating product reach along with future medical aspirations of the company.
Below is a rough summary of equity value of the company both now and if options were excised, which is before any sales or revenue.
If all goes well with distribution sales, this will be a serious re-rate for the company.
Add to My Watchlist
What is My Watchlist?
